Medi-Tate Investment Agreement

Senior Partner Atir Jaffe and Senior Associate Yael Shimon-Many represented Medi-Tate Ltd., a company developing products for treating urethral and prostate diseases, in an investment agreement totaling up to $10 million, at a company’s valuation of 50 million (post-money). Up to $8 million will be invested by a strategic investor, and up to $2 million will be invested, at the company’s sole discretion, by additional investors. Further, the parties entered into an option agreement, in which the strategic investor was given an option to purchase the company at a company’s valuation of between $100-200 million. CLICK HERE to read more (Hebrew).